Bristol-Myers Squibb tabs Christopher Boerner as chief commercial officer

Bristol-Myers Squibb on Tuesday revealed that Christopher Boerner has been selected as chief commercial officer effective immediately. Boerner, who most recently served as the company's head of international markets, is replacing Murdo Gordon, who leftthe drugmaker earlier this month to join Amgen as its executive vice president  (EVP) of global commercial operations.

Giovanni Caforio, chief executive at Bristol-Myers Squibb, said "[Boerner] brings a deep knowledge of specialty-care markets, a clear focus on innovation and a proven track record of successful execution."

Boerner joined Bristol-Myers Squibb in 2015 as head of the US commercial organisation. The company noted that prior to that, he had served as EVP of commercial operations for Seattle Genetics and led the marketing team at Dendreon. Boerner also worked at Genentech for several years before its eventual acquisition by Roche, serving in a variety of commercial roles, including director of marketing for Avastin (bevacizumab) and associate director of oncology market development.

"I'm very excited to lead such a talented and diverse commercial team globally," commented Boerner about his new position, adding "along with my commercial colleagues, I look forward to continuing to help [Bristol-Myers Squibb] deliver on our mission of bringing transformational medicines to patients."

 --------------------------------------------------------------------------------------------------------------------------

Editor's Note:

To apply for becoming a contributor of en-CPhI.cn,

welcome to send your CV and sample works to us,

Email: Julia.Zhang@ubmsinoexpo.com.